化合物CCF642 T6800

Product Introduction
Bioactivity


英文名: CCF642

描述: CCF642 (AC1LYELL) 是蛋白质二硫键异构酶抑制剂(IC50:2.9 μM)。它在多发性骨髓瘤细胞中引起急性内质网应激，并伴随凋亡诱导的钙释放，表现出广泛的抗多发性骨髓瘤作用。

激酶实验: Inhibition of CB-839 on rHu-GAC: The enzymatic activity is measured in assay buffer containing 50 mM Tris-Acetate pH 8.6, 150 mM K2HPO4 , 0.25 mM EDTA, 0.1 mg/mL bovine serum albumin, 1 mM DTT, 2 mM NADP+ and 0.01% Triton X-100. To measure inhibition, the inhibitor (prepared in DMSO) is first pre-mixed with glutamine and glutamate dehydrogenase (GDH) and reactions are initiated by the addition of rHu-GAC. Final reactions contains 2 nM rHu-GAC, 10 mM glutamine, 6 units/mL GDH and 2% DMSO. Generation of NADPH is monitored by fluorescence (Ex340/Em460 nm) every minute for 15 minutes on a SpectraMax M5e plate reader. Relative fluorescence units (RFU) are converted to units of NADPH concentration (μM) using a standard curve of NADPH. Each assay plate incorporates control reactions that monitores the conversion of glutamate (1 to 75 μM) plus NADP+ to α-ketoglutarate plus NADPH by GDH. Under these assay conditions, up to 75 μM glutamate is stoichiometrically converts to α-ketoglutarate/NADPH by GDH. Initial reaction velocities are calculated by fitting the first 5 minutes of each progress curve to a straight line. Inhibition curves are fitted to a four-parameter dose response equation of the form: % activity = Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)).

体外活性: In vitro, CCF642 inhibits PDI reductase activity about 100-fold more potently than the structurally distinct established inhibitors PACMA 31 and LOC14. Computational modeling suggests a novel covalent binding mode in active-site CGHCK motifs. CCF642 causes acute ER stress in multiple myeloma cells accompanied by apoptosis-inducing calcium release[1].

体内活性: CCF642 displays potent efficacy in an aggressive syngeneic mouse model of multiple myeloma and prolongs the lifespan of C57BL/KaLwRij mice engrafted with 5TGM1-luc myeloma, an effect comparable to the first-line multiple myeloma therapeutic bortezomib[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 7.6 mg/mL (20 mM)


关键字: calcium | Inhibitor | PDI | apoptosis | isomerases | disulfide | CCF 642 | myeloma | protein | multiple | release | CCF-642 | CCF642 | stress | inhibit | anti-multiple

相关库: Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library | Endoplasmic Reticulum Stress Compound Library | Inhibitor Library | Hematonosis Compound Library | Covalent Inhibitor Library | ER stress pathway inhibitor/inducer kit | Bioactive Compound Library

化合物CCF642 T6800信息由TargetMol中国为您提供，如您想了解更多关于化合物CCF642 T6800报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途